利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

52 条记录 (耗时 0.045 秒)

    MODULATION OF THE IMMUNE RESPONSE
    41.
    发明申请
    MODULATION OF THE IMMUNE RESPONSE 审中-公开
    调节免疫应答

    公开(公告)号：US20150225457A1

    公开(公告)日：2015-08-13

    申请号：US14418726

    申请日：2013-07-30

    申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

    发明人： Richard S. Blumberg ,  Vijay K. Kuchroo ,  Yu-Hwa Huang ,  Chen Zhu ,  Ana C. Anderson

    IPC分类号： C07K7/08 ,  A61K38/10 ,  A61K39/395 ,  C07K14/705

    摘要： Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

    摘要翻译： 本文描述了用于调节T细胞耐受性的组合物和方法，其可以通过同时增强或抑制CEACAM1 / TIM3相互作用而被上调或下调。 如本文所述，CEACAM1是TIM3的直接配体，反之亦然的发现已经以顺式和反式表示。 此外，如本文所示，CEACAM1和TIM3在T细胞活化过程中共调节。

    REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION
    44.
    发明申请
    REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION 审中-公开

    公开(公告)号：US20190225701A1

    公开(公告)日：2019-07-25

    申请号：US16336635

    申请日：2017-09-26

    申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

    发明人： Vijay K. Kuchroo ,  Sheng XIAO

    IPC分类号： C07K16/28 ,  A61P37/00 ,  A61P35/00 ,  A61P19/02 ,  A61P29/00 ,  A01K67/027

    摘要： The compositions and methods described herein are based, in part, on the discovery that regulatory B cells (Bregs) differentially express a specific set of coinhibitory molecules, including TIGIT, LAG-3, PD-1, CTLA4, and TIM-3. The data described herein indicate that TIGIT is required for both Breg-mediated tolerance maintenance at the steady state, and inflammation restraint during autoimmune and inflammatory diseases. Accordingly, provided herein are compositions and methods targeting coinhibitory molecules, such as TIGIT, LAG-3, PD-1, CTLA4, and TIM-3, in B cells, as novel therapeutic strategies for modulating immune suppression and treating diseases mediated or impacted by immune suppression mechanisms, such as autoimmune diseases and cancers.